"Pharmaceutical Speed Reading Society" Yan Yuan Pharmaceutical completed the A-round financing KRAS inhibitors approved clinically in China.

August 10, 2020 / Pharmaceutical Information List: Beida Pharmaceuticals ALK inhibitor NSCLC Phase III clinical end point, Via Bio and Langhua Pharmaceuticals reached a strategic integration agreement to accelerate the upgrading of the innovative pharmaceutical industry service chain, Huahai Pharmaceuticals "Omeishatan ester hydrochloride tablets" first imitation is about to be approved in China; Daily fresh medicine news, quick reading with you to pay attention to! Part 1 Policy Brief August 9 14 new confirmed local cases nationwide August 9 0-24 hours, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 49 new confirmed cases, of which 35 cases were imported from abroad (Shanghai 18 cases, Shandong 4 cases, Sichuan 4 cases, Guangdong 3 cases, Shaanxi 3 cases, Liaoning 2 cases, Zhejiang 1 case), 14 local cases (all in Xinjiang);
(National Health And Health Commission) Part 2 has been observed to have completed a US$20 million A-plus round of financing for Yanyuan Pharmaceuticals, announcing that the Company has reached an agreement to raise more than US$20 million in oversubscribed A-round equity financing.
this round will be used to advance its next-generation ROS1/NTRK inhibitor Taletrectinib's global Phase 2 clinical trials and further expand the company's cancer research and development pipeline.
(Pharmaceutical Mission) Jiabao ren and completed the B-plus round financing Jiabaoren and recently announced the completion of nearly 100 million yuan of B-plus round financing, this round of financing will be mainly used for reproductive genetic innovation products and services research and development and promotion.
it is understood that the current round of investors for Apricot Capital, Hao Yue Capital as the exclusive financial adviser.
Ed Bio and Merck reached an accompanying diagnostic cooperation Ed Bio 10 announcement revealed that recently, with Merck signed a cooperation agreement.
"Lung Cancer Multigene Joint Detection Product" developed by Aide Bio based on the PCR technology platform will be used for the accompanying diagnostic registration of Merck MET inhibitor Tepotinib in Japan.
(Eu-European Health Official) Via Bio and Langhua Pharmaceuticals reached a strategic integration agreement to accelerate the upgrading of the innovative pharmaceutical industry service chain 9, Via Bio entered into a share purchase agreement, according to which Via Bio agreed to acquire and the seller agreed to jointly sell 80% of Langhua Pharmaceuticals at a cost of RMB2.56 billion.
This strategic integration will give full play to the business synergies in the research and development, design and production of Via Bio and Longhua Pharmaceuticals in the global pharmaceutical market, and will be of great strategic significance for the company to integrate vertically in the industrial chain and expand into CDMO business, and establish an integrated one-stop drug service platform.
(U.S. News Agency) Part 3 Drug News Beda Pharmaceuticals ALK Inhibitor NSCLC Phase III Clinical End Date, Beda Pharmaceutical Holdings Subsidiary Xcovery Holdings released the results of its new generation of ALK inhibitor Ensatini hydrochloric acid and similar drug Pfizer Xalkori comparison of the International Multi-Center Phase 3 clinical study results.
results showed that the mid-progress life of patients with ALK-positive non-small cell lung cancer treated with enchained was significantly longer than that of patients treated with ketamine, reaching the primary endpoint.
(Sina Pharmaceutical News) Pan-KRAS inhibitors approved in China clinically can target all "major KRAS mutants" CDE latest publicity, Blinger Ingehan class 1 new drug BI 1701963 tablets obtained clinical trials implied license to develop adaptive to local late-stage or metastatic colorectal cancer with KRAS mutation-positive patients.
BI 1701963 is the first inhibitor of all major KRAS mutants targeted by Blinger Ingehan and is expected to block the activity of KRAS mutants in 15% of cancers.
(CDE) Baiotai Adamu anti-China approved treatment of non-infectious vinestrial inflammation BaiOtai announced that the State Drug Administration has approved Greli ® (Adamum monoanti injection) for the treatment of adult non-infectious intermediate vinesitis, post-vine vinesitis and whole grape vinesitis patients.
This is the fifth adaptation approved by Greely® in China, marking Greely® after rheumatoid immunology, dermatology, digestive department, entered the field of ophthalmology this new treatment.
(immediate drug news) Apatamine second adaptive disorder in China was approved in recent days, according to the NMPA official website, Johnson and Johnson's Xi'an Yangsen apatamine tablets in China's second listing application became "in the approval", which means that the drug is about to win a second adaptation in China, guessing that the new adaptive disorder is metastatic desceitative prostate cancer.
(CPhI Pharmaceutical Online) is day sunny "fluvys group injection" first imitation is about to be approved recently, is day sunny new class 4 generic drug "fluvys group injection" listing application into the approval state, is expected to be approved to become the first imitation in China.
February 11th, the "Fluvis Group Injection" was approved by the FDA and the German Federal Drug and Medical Device Administration's drug marketing license, respectively.
(Insight database) Huahai Pharmaceuticals "Omeishatan ester hydrochloroquine tablets" is about to be approved in China, Huahai Pharmaceuticals in China submitted four types of generic drugs Omeishatan hydrochloroquine tablets market application into the "in the approval" stage, is expected to be approved in the near future to become the first imitation in China.
omethalate hydrochloroquine tablets are mainly used to treat hypertension.
(Pharmaceutical Rubik's Cube) Enhua Pharmaceuticals TRV-130 injection market application approved by the U.S. FDA Enhua Pharmaceuticals announced that the company and Trevena in the United States in late April 2018 on the class 1 chemical TRV-130 injections in China to carry out "authorized adaptation" exclusive licensing development and commercialization cooperation agreement.
, licensee Trevena received notification from the FDA that its declared application for a new TRV-130 injection drug had been approved.
(Enhua Pharmaceuticals Announcement)